financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Hold Opinion On Shares Of Resmed Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Hold Opinion On Shares Of Resmed Inc.
Apr 26, 2024 7:16 AM

09:45 AM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We increase our 12-month target price by $10 to $210, or 27.0x our FY 24 (Jun.) EPS estimate, a discount to RMD's three-year average forward P/E of 33.2x, but close to in line with peers, which are trading at an average forward P/E of 26.6x. We raise our FY 24 EPS estimate by $0.35 to $7.77 and FY 25's by $0.30 to $8.36. RMD posted FQ3 adj. EPS of $2.13 vs. $1.68, $0.22 above consensus, driven by a top-line beat of 2%. Revenue from the U.S., Canada, and Latin America rose 9% Y/Y during FQ3 and sales in Europe, Asia, and other markets were up 3% Y/Y, while Software-as-a-Service increased 8% Y/Y. The adj. gross margin in FQ3 expanded 240 basis points Y/Y to 58.5%, which was driven by reduced freight expense, favorable product mix, an increase in device average selling prices, and manufacturing cost improvements. We anticipate higher freight costs in FQ4 due to the disruption in shipping lanes in the Red Sea, which should contribute to a sequential contraction in the gross margin of about 50 basis points in FQ4.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Hold Opinion On Shares Of Resmed Inc.
Research Alert: CFRA Maintains Hold Opinion On Shares Of Resmed Inc.
Apr 26, 2024
09:45 AM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We increase our 12-month target price by $10 to $210, or 27.0x our FY 24 (Jun.) EPS estimate, a discount to RMD's three-year average forward P/E of 33.2x, but close...
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Gentex Corporation
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Gentex Corporation
Apr 26, 2024
09:00 AM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month price target by $2 to $40, based on a '25 P/E of 16.3x, a discount to GNTX's 5-year mean forward P/E of 18.4x. We maintain our...
Research Alert: CFRA Keeps Hold Opinion Of Shares Of Cnx Resources Corporation
Research Alert: CFRA Keeps Hold Opinion Of Shares Of Cnx Resources Corporation
Apr 26, 2024
09:35 AM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Our 12-month target of $25, up $3, reflects a 7.3x multiple of EV to projected '24 EBITDA, below its peers. We think a peer discount is merited due to CNX's...
Research Alert: CFRA Retains Buy Opinion On Adss Of Orange S.a.
Research Alert: CFRA Retains Buy Opinion On Adss Of Orange S.a.
Apr 26, 2024
09:15 AM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our target price of USD13, which implies a 2024 consensus EV/EBITDA of 5.6x, comparable to its historical EV/EBITDA level of around 5x. We think the valuation is fair...
Copyright 2023-2026 - www.financetom.com All Rights Reserved